ArticleBMC genomics2022
Mendelian randomization of circulating proteome identifies actionable targets in heart failure.
Article in BMC genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Large-Scale Proteomic Profiling of Incident Heart Failure and Its Subtypes in Older Adults.Circulation. Genomic and precision medicine · 2026Article
- Interactive Effect of Plasma Lipidome on Neuropsychiatric Disorders: A Bidirectional Mendelian Randomization Study.Molecular neurobiology · 2025Article
- Mendelian randomization of plasma lipidome, inflammatory proteome and heart failure.ESC heart failure · 2024Article
- Ancestrally diverse genome-wide association analysis highlights ancestry-specific differences in genetic regulation of plasma protein levels.medRxiv : the preprint server for health sciences · 2024Article
- Clinical-transcriptional prioritization of the circulating proteome in human heart failure.Cell reports. Medicine · 2024Article
- Mendelian randomization reveals interactions of the blood proteome and immunome in mitral valve prolapse.Communications medicine · 2024Article
- Identification of Circulating Plasma Proteins as a Mediator of Hypertension-Driven Cardiac Remodeling: A Mediation Mendelian Randomization Study.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Proteomic Associations of Adverse Outcomes in Human Heart Failure.Journal of the American Heart Association · 2024Article
- Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9.BMC medical genomics · 2024Article
- Genetic Evidence for the Causal Association of Circulating Cytokines and Growth Factors With Coronary Artery Disease.Journal of the American Heart Association · 2024Article
- Identifying novel potential drug targets for endometriosis via plasma proteome screening.Frontiers in endocrinology · 2024Article
- The causal relationship between human brain morphometry and knee osteoarthritis: a two-sample Mendelian randomization study.Frontiers in genetics · 2024Article
- Mendelian randomization reveals plasminogen as a common therapeutic target for myocardial infarction and atrial fibrillation.Journal of cardiovascular and thoracic research · 2024Article
- Proteome-wide analysis reveals potential therapeutic targets for Colorectal cancer: a two-sample mendelian randomization study.BMC cancer · 2023Article
- Prioritization of nasal polyp-associated genes by integrating GWAS and eQTL summary data.Frontiers in genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a prevalent cause of mortality and morbidity. The molecular drivers of HF are still largely unknown.
resultsWe aimed to identify circulating proteins causally associated with HF by leveraging genome-wide genetic association data for HF including 47,309 cases and 930,014 controls. We performed two-sample Mendelian randomization (MR) with multiple cis instruments as well as network and enrichment analysis using data from blood protein quantitative trait loci (pQTL) (2,965 blood proteins) measured in 3,301 individuals. Nineteen blood proteins were causally associated with HF, were not subject to reverse causality and were enriched in ligand-receptor and glycosylation molecules. Network pathway analysis of the blood proteins showed enrichment in NF-kappa B, TGF beta, lipid in atherosclerosis and fluid shear stress. Cross-phenotype analysis of HF identified genetic overlap with cardiovascular drugs, myocardial infarction, parental longevity and low-density cholesterol. Multi-trait MR identified causal associations between HF-associated blood proteins and cardiovascular outcomes. Multivariable MR showed that association of BAG3, MIF and APOA5 with HF were mediated by the blood pressure and coronary artery disease. According to the directional effect and biological action, 7 blood proteins are targets of existing drugs or are tractable for the development of novel therapeutics. Among the pathways, sialyl Lewis x and the activin type II receptor are potential druggable candidates.
conclusionsIntegrative MR analyses of the blood proteins identified causally-associated proteins with HF and revealed pleiotropy of the blood proteome with cardiovascular risk factors. Some of the proteins or pathway related mechanisms could be targeted as novel treatment approach in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.